# Changes in Blood DNA CpG Methylation Levels in Response to Methadone Maintenance Treatment: Epigenome-Wide Longitudinal Study

**Authors:** Orna Levran, Yuli Kim, Justin Li, Anat Sason, Miriam Adelson, Einat Peles

PMC · DOI: 10.3390/epigenomes10010018 · Epigenomes · 2026-03-05

## TL;DR

This study explores how methadone treatment affects DNA methylation in blood over time, identifying genes and pathways potentially influenced by the treatment.

## Contribution

The study provides new insights into the epigenetic effects of methadone maintenance treatment on blood DNA methylation.

## Key findings

- 1881 differentially methylated probes were identified after methadone maintenance treatment.
- Genes like ADORA2A, BDNF, and CACNA1D were associated with methylation changes linked to substance use disorder.
- The most overrepresented pathway was small GTPase-mediated signal transduction and actin cytoskeleton organization.

## Abstract

Background/Objectives: Methadone maintenance treatment (MMT) is one of the major pharmacotherapies for opioid use disorder. The underlying mechanisms of addiction and the treatment response are only partially understood. The study’s main goal was to identify differential DNA CpG methylation that occurred in response to MMT. Methods: Toward this goal, we have conducted a longitudinal epigenome-wide study of blood samples from 64 patients at the beginning and after 1–3 years of MMT, using a linear mixed model. Results: A total of 1881 differentially methylated probes (DMPs) were identified (FDR < 0.05), controlling for sex, age, estimates of blood cell proportions, and the first two principal components based on genome-wide SNP genotypes. Among the genes annotated to the top DMPs are DGLUCY, NXNL2, SOX10, and NPAS3. Several genes associated with substance use disorder were annotated by the identified DMPs, including ADORA2A, BDNF, CACNA1D, CREB1, CRHR1, CRY1, DNMT3B, GABRD, GNAS, GRIP1, OXR1, PRKACB, SCN2A, and SCN3A. The most overrepresented pathway is the small GTPase-mediated signal transduction pathway, and the most overrepresented process is the actin cytoskeleton organization. Conclusions: The study provides preliminary insight into the epigenetic effect of MMT. Future studies will have to confirm the DMPs, assess their impact on gene expression, and determine their clinical relevance.

## Linked entities

- **Genes:** DGLUCY (D-glutamate cyclase) [NCBI Gene 80017], NXNL2 (nucleoredoxin like 2) [NCBI Gene 158046], SOX10 (SRY-box transcription factor 10) [NCBI Gene 6663], NPAS3 (neuronal PAS domain protein 3) [NCBI Gene 64067], ADORA2A (adenosine A2a receptor) [NCBI Gene 135], BDNF (brain derived neurotrophic factor) [NCBI Gene 627], CACNA1D (calcium voltage-gated channel subunit alpha1 D) [NCBI Gene 776], CREB1 (cAMP responsive element binding protein 1) [NCBI Gene 1385], CRHR1 (corticotropin releasing hormone receptor 1) [NCBI Gene 1394], CRY1 (cryptochrome circadian regulator 1) [NCBI Gene 1407], DNMT3B (DNA methyltransferase 3 beta) [NCBI Gene 1789], GABRD (gamma-aminobutyric acid type A receptor subunit delta) [NCBI Gene 2563], GNAS (GNAS complex locus) [NCBI Gene 2778], GRIP1 (glutamate receptor interacting protein 1) [NCBI Gene 23426], OXR1 (oxidation resistance 1) [NCBI Gene 55074], PRKACB (protein kinase cAMP-activated catalytic subunit beta) [NCBI Gene 5567], SCN2A (sodium voltage-gated channel alpha subunit 2) [NCBI Gene 6326], SCN3A (sodium voltage-gated channel alpha subunit 3) [NCBI Gene 6328]

## Full-text entities

- **Genes:** GABRD (gamma-aminobutyric acid type A receptor subunit delta) [NCBI Gene 2563] {aka EIG10, EJM7, GABAARdelta, GEFSP5}, OPRM1 (opioid receptor mu 1) [NCBI Gene 4988] {aka LMOR, M-OR-1, MOP, MOR, MOR1, OPRM}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, SOX10 (SRY-box transcription factor 10) [NCBI Gene 6663] {aka DOM, PCWH, SOX-10, WS2E, WS4, WS4C}, Sox10 (SRY-box transcription factor 10) [NCBI Gene 29361], DNMT3B (DNA methyltransferase 3 beta) [NCBI Gene 1789] {aka FSHD4, ICF, ICF1, M.HsaIIIB}, DGLUCY (D-glutamate cyclase) [NCBI Gene 80017] {aka C14orf159}, OXR1 (oxidation resistance 1) [NCBI Gene 55074] {aka CHEGDD, Nbla00307, TLDC3}, USP37 (ubiquitin specific peptidase 37) [NCBI Gene 57695], CACNA1D (calcium voltage-gated channel subunit alpha1 D) [NCBI Gene 776] {aka CACH3, CACN4, CACNL1A2, CCHL1A2, Cav1.3, PASNA}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, GRIP1 (glutamate receptor interacting protein 1) [NCBI Gene 23426] {aka FRASRS3, GRIP}, NPAS3 (neuronal PAS domain protein 3) [NCBI Gene 64067] {aka MOP6, PASD6, bHLHe12}, ARGFX (arginine-fifty homeobox) [NCBI Gene 503582], CREB1 (cAMP responsive element binding protein 1) [NCBI Gene 1385] {aka CREB, CREB-1}, RTP4 (receptor transporter protein 4) [NCBI Gene 64108] {aka IFRG28, Z3CXXC4}, GNAS (GNAS complex locus) [NCBI Gene 2778] {aka AHO, AIMAH1, C20orf45, GNAS1, GPSA, GSA}, Nxnl2 (nucleoredoxin-like 2) [NCBI Gene 75124] {aka 4930519N16Rik, Rdcvf2}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, PRKACB (protein kinase cAMP-activated catalytic subunit beta) [NCBI Gene 5567] {aka CAFD2, PKA C-beta, PKACB}, CRHR1 (corticotropin releasing hormone receptor 1) [NCBI Gene 1394] {aka CRF-R, CRF-R-1, CRF-R1, CRF1, CRFR-1, CRFR1}, SCN2A (sodium voltage-gated channel alpha subunit 2) [NCBI Gene 6326] {aka BFIC3, BFIS3, BFNIS, DEE11, EA9, EIEE11}, CYP2C19 (cytochrome P450 family 2 subfamily C member 19) [NCBI Gene 1557] {aka CPCJ, CYP2C, CYPIIC17, CYPIIC19, P450C2C, P450IIC19}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, SCN3A (sodium voltage-gated channel alpha subunit 3) [NCBI Gene 6328] {aka DEE62, EIEE62, FFEVF4, NAC3, Nav1.3}, ADORA2A (adenosine A2a receptor) [NCBI Gene 135] {aka A2aR, ADORA2, RDC8}, FAM107B (family with sequence similarity 107 member B) [NCBI Gene 83641] {aka C10orf45, HITS}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CRY1 (cryptochrome circadian regulator 1) [NCBI Gene 1407] {aka DSPD, PHLL1}, DRD1 (dopamine receptor D1) [NCBI Gene 1812] {aka D1R, DADR, DRD1A}, FAM107A (family with sequence similarity 107 member A) [NCBI Gene 11170] {aka DRR1, TU3A}, NXNL2 (nucleoredoxin like 2) [NCBI Gene 158046] {aka C9orf121, RDCVF2, RdCVF2L}
- **Diseases:** OUD (MESH:D009293), chronic inflammation (MESH:D007249), chronic pain (MESH:D059350), MMT (MESH:D007319), multiple sclerosis (MESH:D009103), DMPs (MESH:D012734), heroin abuse (MESH:D006556), male infertility (MESH:D007248), pain (MESH:D010146), Mental Disorders (MESH:D001523), addiction (MESH:D019966), sperm abnormalities (MESH:C567467), neurodevelopmental disorders (MESH:D002658), injury to (MESH:D014947)
- **Chemicals:** dopamine (MESH:D004298), buprenorphine (MESH:D002047), D-glutamate (MESH:D018698), Bisulfite (MESH:C042345), naltrexone (MESH:D009271), morphine (MESH:D009020), cocaine (MESH:D003042), benzodiazepine (MESH:D001569), alcohol (MESH:D000438), 5-methylcytosine (MESH:D044503), fentanyl (MESH:D005283), Methadone (MESH:D008691), D-serine (-), heroin (MESH:D003932)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Nicotiana tabacum (American tobacco, species) [taxon 4097], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** rs255105, rs5326

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13024794/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13024794/full.md

## References

52 references — full list in the complete paper: https://tomesphere.com/paper/PMC13024794/full.md

---
Source: https://tomesphere.com/paper/PMC13024794